Haluk Yuzugullu

Medicine · Health Sciences

12h-index3.0kcitations26works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(7), PI3K/AKT/mTOR signaling in cancer(5), DNA Repair Mechanisms(4), Telomeres, Telomerase, and Senescence(4), Ubiquitin and proteasome pathways(4)

Publications26 total

A phase 1/2 dose escalation study of the oral DNA polymerase theta inhibitor (POLQi) GSK4524101 ± niraparib in adults with advanced or metastatic solid tumors.
Journal of Clinical Oncology·2025
First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors.
Journal of Clinical Oncology·2024
Abstract CT169: First-in-human, phase 1/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors
Cancer Research·2024· 5 cited
Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma
Journal of Gastrointestinal Cancer·2021· 5 citedOpen Access
Evaluation of ATAD2 As a Potential Target in Hepatocellular Carcinoma
2021Open Access
Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells
UNC Libraries·2019Open Access
Abstract 700: Development of a second-generation TRAIL agonist and predictive biomarker profile for colorectal cancer
Molecular and Cellular Biology / Genetics·2019
Abstract 700: Development of a second-generation TRAIL agonist and predictive biomarker profile for colorectal cancer
Cancer Research·2019
Abstract 22: MM-161, a first-in-class pan-FGFR antibody
Cancer Research·2017
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers
Cancer Cell·2017· 97 citedOpen Access
NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K–AKT and JAK–STAT3 pathways
Cell Discovery·2016· 21 citedOpen Access
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Cancer Cell·2016· 474 citedOpen Access
A PI3K p110β–Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis
Nature Communications·2015· 47 citedOpen Access
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Cell·2015· 482 citedOpen Access
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
DSpace@MIT (Massachusetts Institute of Technology)·2015Open Access
Targeted Therapy for Hepatocellular Carcinoma: What`s New?
Liver Research - Open Journal·2015Open Access
がんのPI3K : アイソフォームの異なる役割、活性化の機序および治療標的
Cancer and Clinical Oncology·2015Open Access
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Nature reviews. Cancer·2014· 1.3k citedOpen Access
Abstract 4775: PI3K-p110β is required for leukemic transformation and HSC depletion in the absence of Pten
Cancer Research·2014
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α
Journal of Clinical Investigation·2014· 54 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Jean J. Zhao(9), Mehmet Öztürk(9), Thanh Von(5), Şerif Şentürk(4), Neşe Atabey(4), Özge Gürsoy-Yüzügüllü(4), Lauren M. Thorpe(3), Nuri Öztürk(3), Esra Erdal(3), Kamil Can Akçalı(3), Sevgi Baǧışlar(3), Çigdem Özen(3), Kira Gritsman(3), Linda K. Clayton(3), Thomas M. Roberts(3), Hani Alotaibi(3), Vivek Samnotra(3), V. V. Moroz(3), Luda Shtessel(3), Patrick Hanafin(3)